A Phase II Study of Clinical Outcomes of 3-Week Cycles of Irinotecan and S-1 in Patients with Previously Untreated Metastatic Colorectal Cancer: Influence of theUGT1A1andCYP2A6Polymorphisms on Clinical Activity

Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping

(2017) B. C. Goh et al.   JOURNAL OF CLINICAL ONCOLOGY

A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

(2011) E Marcuello et al.   BRITISH JOURNAL OF CANCER

Phase II study of S-1 combined with oxaliplatin as therapy for patients with metastatic biliary tract cancer: influence of the CYP2A6 polymorphism on pharmacokinetics and clinical activity

(2011) K-p Kim et al.   BRITISH JOURNAL OF CANCER

A phase I study of combination therapy with S-1 and irinotecan in patients with previously untreated metastatic or recurrent colorectal cancer

(2011) Yoon Hee Choi et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

A phase II study of combination therapy with irinotecan and S-1 (IRIS) in patients with advanced colorectal cancer

(2010) Manabu Shiozawa et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

(2010) Hitoshi Kusaba et al.   CANCER SCIENCE

Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)

(2010) Kei Muro et al.   LANCET ONCOLOGY

Phase I/II study of sequential therapy with irinotecan and S-1 for metastatic colorectal cancer

(2009) T Yoshioka et al.   BRITISH JOURNAL OF CANCER

Predictive Role of the UGT1A1, UGT1A7, and UGT1A9 Genetic Variants and Their Haplotypes on the Outcome of Metastatic Colorectal Cancer Patients Treated With Fluorouracil, Leucovorin, and Irinotecan

(2009) Erika Cecchin et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of S-1 Combined with Irinotecan (CPT-11) in Patients with Advanced Colorectal Cancer

(2009) A. Tsunoda et al.   ONCOLOGY

Genetic Variations and Haplotypes of UDP-glucuronosyltransferase 1A Locus in a Korean Population

(2009) Sung Su Yea et al.   THERAPEUTIC DRUG MONITORING

UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study

(2008) D M Kweekel et al.   BRITISH JOURNAL OF CANCER

UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma

(2008) Chun-Yu Liu et al.   CANCER

The CYP2A6*4 Allele Is Determinant of S-1 Pharmacokinetics in Japanese Patients With Non-small-cell Lung Cancer

(2008) Y Kaida et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Importance of UDP-glucuronosyltransferase 1A1∗6 for irinotecan toxicities in Japanese cancer patients

(2007) Kimie Sai et al.   CANCER LETTERS